{"id":"NCT01365546","sponsor":"Octapharma","briefTitle":"Wilate in Subjects With Von Willebrand Disease Who Undergo Surgery","officialTitle":"Prospective, Open-Label, Multi-Center, Phase III CLinical Study to Investigate the Efficacy and Safety of Human Factor VWF/FVIII Concentrate (Wilate) in Subjects With Inherited Von Willebrand Disease Who Undergo Surgical Procedures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-06","primaryCompletion":"2014-02","completion":"2014-04","firstPosted":"2011-06-03","resultsPosted":"2015-03-09","lastUpdate":"2015-03-09"},"enrollment":30,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Prevent Bleeding in Major Surgery"],"interventions":[{"type":"BIOLOGICAL","name":"human VWF/FVIII concentrate","otherNames":[]}],"arms":[{"label":"human VWF/FVIII concentrate","type":"EXPERIMENTAL"}],"summary":"Proportion of surgeries in which the primary endpoint (overall assessment) is classified as success.","primaryOutcome":{"measure":"Overall Hemostatic Efficacy (Success or Failure) of Wilate, Based on the Intra-operative Assessment of the Surgeon and the Post-operative Assessment by the Investigator Using a 4-point Ordinal Efficacy Scale.","timeFrame":"30 Days","effectByArm":[{"arm":"Minor Surgery","deltaMin":9,"sd":null},{"arm":"Major Surgery","deltaMin":20,"sd":null},{"arm":"All Surgeries","deltaMin":29,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":15,"countries":["United States","Bulgaria","India","Italy","Oman","Poland","Romania","South Africa","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":41},"commonTop":["Procedural Pain","Nausea","Vomiting","Pain","Pyrexia"]}}